Identify underlying allergy aetiology


Search for common clues to complicating factors, including blephartis and dry eye

Aplethora of effective antihistamines does little to relieve ocular allergies when complicated by other concomitant factors, said Dr Michael B. Raizman, at the 29th annual Current Concepts in Ophthalmology conference held in association with the Wilmer Eye Institute.

"You would think allergy would be easy to treat," said Dr Raizman, associate professor of ophthalmology, Tufts University School of Medicine, Boston, Massachusetts, USA. "We have the best antihistamines in the world. They are incredibly effective, yet our patients still come in complaining. They've tried everything, and nothing is working. Why is that?"

Obvious allergic conjunctivitis

This condition is seasonal and caused by pollens in the air. Patients may complain that the overthecounter (OTC) eye drops they use no longer work, Dr Raizman said. The most common reason for this type of failure for allergy treatment is the presence of other conditions of the ocular surface.

"[More than] 75% of treatment failures are caused by either dry eye or blepharitis," he said.

"You must treat the allergy and the under­lying dry eye or blepharitis as well," Dr Raizman said. "Sometimes, many patients can have all three of these - to varying degrees."

The presence of dry eye may not always be obvious. In such cases, lissamine green staining and rose bengal staining are often useful.

"Try to think of all three together, and treat all of them," he said. "Patients may be describing what sound to you like allergies. You can treat their allergies all you want, but if their blepharitis is bothering them, they will view the allergy treatment as a failure."

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.